The Department of Oncology within the College of Medicine operates as an independent unit. Its members are either employed by or contracted with the Saskatchewan Cancer Agency, and they work out of two primary locations: the Saskatoon Cancer Centre in Saskatoon and the Allan Blair Cancer Centre in Regina. Our team is highly interdisciplinary comprising of physicians, physicists, epidemiologists, and research scientists who are based primarily in the Health Sciences Building at the University of Saskatchewan. Each member holds an academic appointment within the College of Medicine underscoring our dual commitment to clinical service and academic excellence. This distinctive composition enables a comprehensive approach to cancer care covering a wide range of specialties including medical oncology, radiation oncology, gynecologic oncology, and both general and malignant hematology. Our diverse expertise facilitates quality patient care along with creating a strong learning environment for training healthcare professionals. Additionally, our commitment to cancer research allows us to explore innovative treatments and contribute to advancements in oncology. Our mission is to provide patient-centered cancer services across Saskatchewan focusing on prevention, early detection, effective treatment, and innovative research. We are dedicated to the continual improvement of patient outcomes and the expansion of knowledge within the oncology field. Moreover, we are devoted to maintaining high standards in education and training for the next generation of healthcare providers. Through these efforts, we strive to enhance patient outcomes and advance the field of oncology.
Oncology Specialties
Medical Oncology is a sub-specialty of internal medicine dedicated to the diagnosis, treatment, and management of cancer. The field of Medical Oncology is constantly evolving, driven by research and the development of new treatment modalities. Recent advances include the expansion of targeted therapies and immunotherapies which aim to attack cancer cells while sparing healthy tissues, leading more precisely to more effective treatments. Precision medicine, where treatments are tailored to the genetic makeup of a cancer, is also becoming more common.
Medical oncologists are specialists who possess an in-depth understanding of the management of various types of cancer. Their expertise extends beyond the prescription of systemic therapy for a specific cancer. They are also skilled in assessing the overall health of patients, considering how patient-related and other factors may impact cancer treatment. This holistic approach is crucial for formulating the most effective treatment strategies while minimizing treatment-related toxicities.
The scope of work of a medical oncologist is broad, encompassing patient care from diagnosis through the course of the disease. This includes explaining the diagnosis and stage of cancer, discussing treatment options and their potential side effects, and facilitating supportive care and symptom management. Medical oncologists also play a leading role in the coordination of treatment plans, often acting as the primary point of contact among the various specialists involved in a patient's care. This coordination is essential for ensuring that treatments are administered effectively and that patients receive the support they need throughout their journey.
Moreover, medical oncologists are deeply involved in clinical research, testing new therapies, and contributing to the advancement of cancer treatments through clinical trials. This research is critical for discovering more personalized and effective treatment options.
Medical oncologists combine scientific knowledge with empathetic care playing a crucial role in the cancer care team. Their role is integral to the cancer care team offering hope and guidance to patients and their families during some of the most challenging times of their lives. Through their dedication to patient care, research, and education, medical oncologists continue to make significant contributions to the field of oncology improving outcomes and transforming the landscape of cancer treatment.
Medical Oncology Division Heads:
Regina – Dr. Muhammad Khan Saskatoon – Dr. Adnan Zaidi
Radiation Oncology is an important discipline within the field of cancer treatment focusing on the use of high-energy radiation to eradicate cancer cells and control cancer-related symptoms. This specialized branch of oncology plays an important role in the multidisciplinary approach to cancer care often complementing surgery, chemotherapy, and other treatments. Radiation oncology harnesses the power of various forms of radiation and charged particles to target cancer cells with precision, minimizing damage to surrounding healthy tissues.
Radiation oncologists are the medical doctors who specialize in treating cancer with radiation therapy. Their work involves designing and implementing treatment plans that use radiation to combat cancer effectively with a detailed assessment of the patient’s condition including the type and stage of cancer, its location, and the patient's overall health. The radiation oncologists collaborate closely with medical physicists and dosimetrists to plan and calculate the precise dose of radiation needed.
Radiation oncologists are actively involved in patient care before, during, and after radiation therapy. They work within a broader team of healthcare professionals, including radiation therapy technologists, nurses, medical physicists, and others ensuring that care is coordinated and holistic. This team approach facilitates a supportive environment for patients addressing not just the physical impact of cancer, but also the psychological and social aspects of the disease and its treatment.
Innovation and research are central to the field of radiation oncology, with ongoing advances in technology and treatment methods continually enhancing the precision, safety, and effectiveness of radiation therapy. Techniques such as intensity-modulated radiation therapy (IMRT), stereotactic radiosurgery (SRS), and proton therapy represent significant milestones in the ability to target tumors more accurately and with fewer side effects. Through their expertise and dedication, radiation oncologists play a vital role in the evolving landscape of cancer care, contributing to improved outcomes and quality of life for patients.
Radiation Oncology Division Heads:
Regina – Dr. Asim Amjad Saskatoon – Dr. Ali El-Gayed
Hematology is a specialized branch of medicine that focuses on the study, diagnosis, treatment, and prevention of diseases related to the blood and bone marrow, as well as the immunologic, hemostatic (blood clotting), and vascular systems. This complex field encompasses a wide range of benign disorders including anemia, bleeding disorders such as hemophilia, blood cancers like leukemia, lymphoma, and myeloma, and many other less common illnesses.
Hematologists are medical doctors who are specialized in diagnosing and treating blood disorders. Their expertise is not limited to cancers of the blood but extends to all blood-related conditions. Hematologists play a crucial role in patient care, from diagnosis to developing comprehensive treatment plans that may involve targeted medicine, blood transfusions, chemotherapy, bone marrow transplants, or cellular therapy. The work of a hematologist often intersects with various medical fields. This multidisciplinary approach ensures a holistic treatment plan tailored to the individual needs of each patient.
Hematologists are deeply involved in the longitudinal care of their patients, especially those with chronic conditions. They provide ongoing assessment and management to monitor the progress of the disease, adjust treatments as necessary, and address any emerging complications. Their role is not just confined to direct patient care; hematologists are also active in clinical research and teaching, contributing to the education of future physicians and the development of new therapies that continue to advance the field. Through clinical trials and laboratory research, they seek to better understand the underlying mechanisms of blood disorders aiming to improve diagnostic techniques, treatment modalities, and ultimately, patient outcomes.
The field of hematology is characterized by rapid advancements in technology and medicine. Hematologists, by applying the latest research findings to clinical practice, are constantly seeking better ways to care for their patients. Through their specialized knowledge and compassionate care, hematologists play a vital role in enhancing the health and well-being of those affected by blood disorders.
Stem cell transplants and CAR T-cell therapy are two innovative treatments in the field of hematology, offering new hope for patients with certain blood cancers and other severe blood-related diseases. Both stem cell transplants and CAR T-cell therapy are complex, high-risk treatments that require a multidisciplinary approach. Hematologists, in collaboration with a team of specialists, are integral to managing these therapies. They assess the suitability of patients for these treatments, oversee the collection and modification of cells, manage the administration of therapy, and monitor patients for adverse effects and response to treatment. Given the potential for severe side effects, such as cytokine release syndrome (CRS) in CAR T-cell therapy, hematologists' expertise in managing these complications is critical.
Through their dedication to patient care, excellence in education, and research, hematologists continue to make significant contributions to the field by teaching future healthcare providers, improving outcomes, and transforming the landscape of the treatment of both general and malignant hematology.
General Hematology Division Heads:
Regina – Dr. Ibraheem Othman Saskatoon – Dr. Kelsey Brose
Malignant Hematology Division Heads:
Regina – Dr. Ibraheem Othman Saskatoon – Dr. Waleed Sabry
Director of Stem Cell Transplant and Cellular Therapy Program:
Dr. Mohamed Elemary
Gynecologic Oncology is a specialized field of oncology that focuses on diagnosing, treating, and managing cancers that affect women's reproductive organs. This includes cancers of the ovary, uterus, cervix, vagina, and vulva. Given the complexity and variety of cancers within this specialty, gynecologic oncology requires a nuanced and highly specialized approach to patient care, integrating surgery, radiation therapy, chemotherapy, and targeted therapies to offer the best possible outcomes.
Gynecologic oncologists are specialists who have expertise in treating gynecologic cancers. Their training includes a residency in obstetrics and gynecology followed by a fellowship in gynecologic oncology, where they gain extensive experience in oncology, surgery, and the complexities of cancer treatment specific to female reproductive organs. This advanced training equips them with the skills to perform complex surgeries, including radical pelvic surgery and minimally invasive surgery such as laparoscopy or robotic-assisted surgery. They also have expertise in prescribing chemotherapy, targeted therapies, and immunotherapies, and collaborate with radiation oncologists when radiation therapy is indicated.
The role of gynecologic oncologists extends beyond the operating room and the clinic. They are deeply involved in the continuum of care for their patients from initial diagnosis through treatment and into survivorship or palliative care as needed. They work closely with a multidisciplinary team that includes radiation oncologists, pathologists, radiologists, nurse specialists, social workers, and other healthcare professionals to ensure a comprehensive and coordinated approach to treatment. This team collaboration is vital for addressing the complex needs of gynecologic cancer patients encompassing physical, emotional, and psychosocial support.
Gynecologic oncologists also play a crucial role in advancing the field through research and clinical trials. They are often involved in studies that explore new surgical techniques, novel chemotherapy drugs, targeted therapies, and innovative approaches to treatment that promise better outcomes. Their work contributes significantly to the evolving understanding of gynecologic cancers and the development of more effective, personalized treatment options.
Gynecologic Oncology Division Heads:
Regina – Dr. Maryam Al-Hayki Saskatoon – Dr. Laura Hopkins
Under Construction
Disease Site Groups
In Saskatchewan, Disease Site Groups play an important role in the comprehensive management of cancer patients across the province. These tumor groups consist of multidisciplinary teams of healthcare professionals specializing in specific cancer types, such as breast cancer, lung cancer, colorectal cancer, and many others. Led by expert oncologists, surgeons, pathologists, radiologists, and other specialists, these groups collaborate to ensure that patients receive personalized, evidence-based care tailored to their individual needs.
Each Disease Site Groups is dedicated to optimizing every aspect of cancer care, from diagnosis and treatment planning to survivorship and supportive care. Through regular tumor board meetings and case discussions, team members collectively review patient cases, evaluate treatment options, and develop customized care plans that prioritize patient outcomes and quality of life. This multidisciplinary approach fosters collaboration, innovation, and continuous improvement in cancer care delivery.
Furthermore, Disease Site Groups play a crucial role in advancing research and quality improvement initiatives in oncology. By participating in clinical trials, outcomes research, and quality improvement projects, these groups contribute to the development of new treatments, protocols, and best practices in cancer care. Ultimately, Disease Site Groups in Saskatchewan are instrumental in ensuring that cancer patients throughout the province receive the highest standard of care and support, empowering them to navigate their cancer journey with confidence and resilience.
Disease Site Group Directors:
Regina - Dr. Haji Chalchal, Medical Oncologist
Saskatoon - Dr. Vijayananda Kundapur, Radiation Oncologist
Medical Oncology Subspecialty Residency Training Program
The Medical Oncology Subspecialty Residency Training Program is one of six subspecialty post-graduate programs currently offered by the University of Saskatchewan (Cardiology, General Internal Medicine, Nephrology, Respirology and Rheumatology).The residency is a two-year program leading to the RCPSC Certification of Special Competence. The program achieved accreditation by the Royal College of Canada in May 2022.The educational CBD program is designed with the application of the principles of adult-centric learning. The resident is expected to be a full participant in their own learning. The educational teaching opportunities and assessments have been thoughtfully aligned with the subcompetencies, milestones and EPAs as outlined by the Royal College of Canada.An annual program evaluation has been designed to ensure that we provide a reflective internal process to assist us in the growth of the program. As the most important stakeholder in the residency program are the residents themselves, we value the input from our resident in this continued growth. Unique features of the curriculum include a collaborative partnership with the University of British Colombia for academic half day, a systemic therapy prescribing curriculum, course work on communication skills, resident case rounds, and a basic science embedded within the academic training.
Faculty members have strong academic research backgrounds in oncology with a track record of peer-reviewed articles in high-impact journals. These members will assist the residents in their pursuit of their own research goals. We have a strong basic science and clinical trials groups, and they are look forward to designing a project with the resident depending on the residents’ career aspirations. Additional graduate work will also be supported, including enrollment in Master level medical education programs if the resident wishes to pursue this. We pride ourselves on providing interprofessional care for the management of cancer patients. We have extensive multi-disciplinary rounds to ensure that we are treating all patients with the highest standards of care. We are well-supported by allied health professionals who assist physicians in guiding the patients and their families throughout the disease trajectory. The Saskatchewan Cancer Agency serves a diverse population with multiple ethnicities including a large Indigenous population. As such, the resident is expected to understand and demonstrate how to provide medical care with cultural sensitivity and competency, as well as their ability to address complex ethical issue with a high level of professionalism.
The overall goal of our medical oncology training program at the University of Saskatchewan is to ensure that you function as a competent and independent medical oncologist in a hospital setting and an outpatient clinic, either in an academic center or in a rural community setting. You will be given three months of elective time and you may choose to tailor your learning in settings such as the inpatient palliative care words and consultation service, rural community medical oncology practice or engage in a basic science or clinical research project including guideline development. You may also wish to concentrate your electives on clinical work in a site-specific area of interest in Saskatoon, Regina or outside the province.
Clinical experiences include out-patient medical oncology, radiation oncology and malignant hematology consultations and follow-up care, in-patient consultations and ward responsibilities and palliative care. The longitudinal clinic begins in the first block of the Core of Discipline training phase. You will be expected to attend oncology conferences with an emphasis on Canadian and national conferences such as the American Society of Clinical Oncology, the National Cancer Institute of Canada, and the Canadian Clinical Trial Group conference. 70% of the training is completed in Saskatoon with the remaining 30% in Regina.
Our program is based out of the Saskatoon Cancer Centre and is affiliated with Royal University Hospital (RUH). In Regina, the program is based out of the Allan Blair Cancer Centre and is affiliated with the Pasqua Hospital. These two main host hospitals are full-service tertiary care teaching facilities. Additional in-patient consultations can take place at City Hospital and St. Paul's Hospital in Saskatoon.
Radiation Oncology and Hematology clinics take place at both cancer center sites. We have a closed oncology admitting ward at RUH, which is supported by clinical associates. There is a dedicated in-patient palliative care ward at St. Paul’s.
This program will enable you to learn continued self-education and self-evaluation. A unique component of the evaluation process is found in your monthly composition of reflective assignments. As well, all of your clinical responsibilities will be transferred to a faculty member to ensure that you have protected time to participate fully in all of the academic activities without distractions. We also support undergraduate medical and post graduate medical educational rotations and you will have the opportunity to expand your knowledge and skills in medical education as you participate in teaching and supervising of junior learners.
The division of medical oncology at the University of Saskatchewan is committed to a transparent, equitable and fair application process. Our process for resident selection will be dependent upon our assessment of their ability to demonstrate the CanMEDS roles in all areas of clinical and academic work.
We will assess the candidate for their ability to master the subcompetencies necessary for a medical oncologist. Our program will look favorably upon attributes, knowledge and behaviors that encompass the characteristics of a successful medical oncologist in the treatment of the cancer patient and their family throughout the disease trajectory. We will assess their cognitive skills, including their attainment of excellent medical knowledge and clinical skills as evaluated through examinations, evidence of administrative and academic work in their internal medicine residency and their problem-solving skills.
Residents will be expected to maintain their internal medicine knowledge while building upon their developing oncology knowledge. We will also assess the candidate for their non-cognitive skills including their communication skills, their ability to collaborate and receive feedback, and their organizational and
leadership skills. We are assessing their engagement in self-reflective personal and professional medical practice, independent learning skills, and their ability to work as a multidisciplinary team with exceptional interpersonal skills.
The demographics of Saskatchewan and the University serves a diverse population with multiple ethnicities including a large Indigenous population. As such, the candidate is one who is able to understand and demonstrate how to provide medical care with cultural sensitivity and competency, as well as their ability to address complex ethical issue with a high level of professionalism.
| Training Stage | Clinical Experience |
| Transiton to Discipline |
|
| Foundatons of Discipline |
|
| Core of Discipline |
|
| Transition to Discipline |
|
| File Component | Criteria |
| CV | Strength of educational attributes, and professional and personal activities as outlined in this document |
| Electives | Electives are evaluated as reflected in medical oncology interest. Electives with the University of Saskatchewan medical oncology group is highly favored. |
| Examinations | MCCQE I score are required, as well as scores if the MCCQE II has been completed. If the candidate is from a US institution, we require their USMLE step 1 and step 2 scores. US training must be assessed by the RCPSC. |
| Extra-Curricular | Skills, behavior and experiences as outlined in this document |
| Leadership Skills | Skills, behavior and experiences as outlined in this document |
| MSPRs | MSPRs are not considered |
| Personal Letters | Interest and knowledge in Medical Oncology at the University of Saskatchewan must be described. Skills, behavior and experiences as outlined in this document |
| Reference Documents | Skills, behavior and experiences as outlined in this documen |
| Reseach/Publications | Research experience, peer reviewed publications, conference presentations, awards, and guideline development are evaluated. |
| Transcrips | Undergraduate medical education transcripts and academic excellence are reviewed |
The program director, members of the residency program committee and the faculty
are flexible, enthusiastic and supportive in assisting you to achieve your career
aspirations.
We welcome your questions and interest in our program. Pleaase contact:
- Program Director: Dr. Dorie-Anna Dueck via the program administrator Ms. Nancy
Groeneveld at Nancy.groeneveld@usask.ca
Research
The Oncology faculty are actively involved in basic science, translational, clinical research including clinical trials, health services, epidemiological and outcomes research. Our research initiatives are led by world-class scientists and researchers whose work is recognized both nationally and internationally. These researchers are contributing important discoveries and innovations that have real-world impacts. Their efforts not only further facilitate our understanding of cancer but also help develop more effective and personalized treatment strategies. Bench research allows us to explore the fundamental biological mechanisms that underpin cancer leading to potential new therapies and technologies. Our clinical research, particularly clinical trials, translates these discoveries into direct patient care, evaluating the efficacy and safety of new treatments before they are widely implemented. This integration of novel therapies into clinical practice can dramatically improve patient outcomes. Meanwhile, our epidemiological and outcomes research focuses on understanding the patterns, causes, and effects of cancer within populations. This broad perspective helps us identify risk factors and determine optimal prevention strategies, enhancing public health efforts across Saskatchewan and beyond.
The Cancer Research Department was established in May 1990 and is home to four research scientists. The research faculty are also members of Cancer Cluster. All research carried out within the Unit is funded by competitive peer-reviewed grants from local and national agencies including the Saskatchewan Cancer Agency, Saskatchewan Health Research Foundation (SHRF), Canadian Institutes of Health Research (CIHR), Natural Sciences and Engineering Research Council (NSERC), Cancer Research Society (CRS), and Canadian Foundation for Innovation (CFI).
The research scientists provide state-of-the-art laboratory experiences with a very active training environment for summer students, fourth-year honors research project students, M.Sc. and Ph.D. level graduate students, and Post-Doctoral Fellows. Each scientist holds an appointment in the Department of Oncology, College of Medicine and is typically also an Associate member of a second department such as Biochemistry, Microbiology and Immunology (BMI), Anatomy, Physiology and Pharmacology (APP), and/or Pathology. The scientists actively participate in these departments and can teach in both undergraduate and graduate courses. This also enables the scientists to supervise graduate students within these academic departments. Undergraduate students within these departments can obtain research experience during the summer months when they are employed as summer students. Many of these students eventually go on to graduate work.
Director of Research – Dr. Deborah Anderson
Clinical trials play a pivotal role in advancing cancer care by providing a platform for the development and evaluation of novel approaches to prevention, detection, and treatment. These studies are designed to explore new drugs, surgical techniques, radiation therapies, or combinations with the ultimate goal of improving outcomes for cancer patients. Importantly, clinical trials are a critical step in the process of bringing new treatments to cancer patients ensuring that they are safe and effective before they are widely adopted.
Participating in a clinical trial offers cancer patients access to novel treatments that may not yet be available through standard care. By enrolling in a trial, patients have the opportunity to receive innovative therapies that could potentially be more effective. Additionally, participation in a clinical trial allows patients to contribute to the advancement of medical knowledge and the development of future treatments for cancer.
The faculty play a crucial role in facilitating access to clinical trials for eligible patients. By staying informed about ongoing research studies and understanding their patients' unique medical histories and treatment goals, they can help identify suitable clinical trial opportunities. Physicians are members of the Canadian Cancer Trials Group (CCTG) and collaborate with major cooperative clinical trials groups such as the National Cancer Institute's (NCI) Cooperative Groups, as well as run investigator initiated studies. Through collaboration with these groups and adherence to ethical guidelines, cancer specialists ensure that patients have access to innovated therapy while upholding the highest standards of care and safety. By actively participating in the clinical trial process, members of the oncology team contribute to advancing medical knowledge and improving outcomes for cancer patients on a broader scale.
Director of Clinical Research – Lynn Dwernychuk
Medical Physics
Medical physics integrates the principles and methodologies of physics with the field of medicine to enhance clinical practices and improve patient outcomes. This specialized area of physics applies its theories and methods to various aspects of healthcare, focusing particularly on the diagnosis, treatment, and monitoring of diseases.
Radiotherapy physics is a critical branch of medical physics that focuses on the application of physics principles in the design, implementation, and optimization of radiation therapy for cancer treatment. Radiotherapy physicists play an important role in ensuring that radiation treatments are not only effective but also as safe as possible for patient. Their expertise in dose calculation is vital for creating detailed treatment plans tailored to the unique anatomy of each patient. These calculations ensure that the prescribed radiation dose is delivered accurately to various depths and contours of the tumor. The physicists' understanding of radiobiology—the study of the biological effects of radiation—further aids in predicting and managing potential side effects in patients, thus enhancing the overall safety and efficacy of treatments.
Overall, the contributions of radiotherapy physicists are foundational to the success of radiation therapy in oncology. Their work ensures that treatment plans are scientifically sound, technologically advanced, and tailored to each patient's specific needs, ultimately contributing to better treatment outcomes.
Director of Medical Physics – Gavin Cranmer-Sargison
Epidemiology and Performance Measurement
Epidemiology and Performance Measurement plays a crucial role in the field of cancer control by providing expertise in various areas such as treatment outcomes, epidemiological research, risk factor surveillance, evaluation, and cancer surveillance. By analyzing data and trends, this team helps to determine the effectiveness of cancer programs, assists in planning interventions, and works towards reducing the burden of cancer on the population of Saskatchewan.
One of the key contributions of Epidemiology and Performance Measurement is the production of the Saskatchewan Cancer Control Report. This report serves as a comprehensive status update on cancer surveillance for the province, offering insights into the current state of cancer incidence, prevalence, and mortality rates. Each edition of the report focuses on a special topic relevant to cancer control efforts, providing detailed information and analysis to inform decision-making and resource allocation.
Overall, the work of Epidemiology and Performance Measurement is instrumental in guiding evidence-based strategies for cancer control, ultimately contributing to better health outcomes and quality of life for the people of Saskatchewan. Through their expertise in data analysis, research, and reporting, this team plays a vital role in the ongoing effort to address cancer in the region.
The work of Epidemiology and Performance Measurement includes:
- Cancer surveillance: collecting, analyzing, interpreting and communicating population-based cancer statistics in Saskatchewan
- Cancer incidence and mortality projections
- Screening programs: ongoing evaluation and monitoring of the screening programs for breast cancer, cervical cancer and colorectal cancer
- Health economic analyses: cost-utility analysis with calculation of quality-adjusted life-years and cost-effectiveness analysis, among others
- Program evaluation and performance measurement
- Statistical and epidemiological research support for clinical studies
- Survey development, analysis and interpretation
- Investigation of potential cancer clusters
- Review of clinical documentation for data abstraction, database development and entry
- Quality assurance for agency data submissions to national and international cancer care organizations
Director of Epidemiology and Performance Measurement – Riaz Alvi
Education
At the Division of Oncology, our primary goal is to provide a medical education that effectively bridges the gap between theoretical learning and practical clinical application. We are committed to ensure that the knowledge learners acquire is directly applicable to the patient care they will deliver at the bedside.
Undergraduate
During the pre-clerkship phase of undergraduate medical education, our faculty members play an important role in shaping the early experiences of our students. They adopt a hands-on approach to teaching that involves active student participation in clinical settings as well as traditional classroom instruction. Our faculty provide mentorship and guidance across a variety of platforms, including clinical rotations, small group sessions, and interactive, case-based learning module.
Postgraduate
See Medical Oncology Subspecialty Residency Training Program
News
Healthy Future Sask Participant Recruitment Update
Healthy Future Sask (HFS) continues to be committed to meeting the project target of recruiting 7,000+ participants for this significant project. Recently, the HFS team attended the Sask Marathon Race Expo to connect with potential participants and share the value of cancer and chronic disease research.
The pre-race expo provided the platform for HFS team members Samantha Mapletoft (Provincial Manager HFS) and Bilal Bare (MPH Practicum student) to engage with attendees. They highlighted the value of the health research platform and emphasized the importance of the information provided by volunteer participants. The booth experience was impactful, with visitors sharing powerful personal stories of the way cancer and chronic disease has affected their lives.
As we head into summer, HFS will continue to attend community events to raise awareness and recruit participants to be part of this legacy project. We invite all SCA employees to help us reach our goal by signing up and sharing the word. Visit the HFS website for more information. Sign up today; together, we can make a difference in the health of our community.
Celebrating Dr. Winston Lok’s Contributions to the Screening Program for Cervical Cancer
Since 2012, Dr. Winston Lok has served as the Medical Advisor for the Screening Program for Cervical Cancer (SPCC). As the first family physician in this role, Dr. Lok has played a key role in several important changes within the program.
During Dr. Lok's tenure, the SPCC moved from the offices on Albert Street in Regina to the new facilities at Harbour Landing. This relocation has helped us expand and improve our services. Dr. Lok was integral in working with the Saskatchewan Registered Nurses Association to initiate training programs that enabled nurses across the province to perform advanced Pap testing. This training facilitated the establishment of pop-up Pap clinics, improving access to essential screening services.
Dr. Lok also co-authored the updated provincial cervical screening guidelines, helping to keep our practices updated. Alongside his SPCC responsibilities, Dr. Lok has actively participated in various health-care initiatives, including serving as the Family Practice Lead for the Regina area, as a member of the Continuing Care Provincial Committee, and on the MySaskHealthRecord committee.
Dr. Lok continues to work as a physician at Gardens Community Health Centre. As Dr. Lok steps down from his role as Medical Advisor, we thank him for his service and contributions to the SPCC and the Saskatchewan Cancer Agency.
We are also pleased to announce that Dr. Joanne Sivertson will assume the role of Medical Advisor for the SPCC in May 2024. We anticipate her contributions and leadership will greatly benefit the program.
Please join us in expressing gratitude to Dr. Lok for his service and in welcoming Dr. Sivertson to her new position.
Division of Oncology Transitions to The Department of Oncology
On April 20, 2024, the University of Saskatchewan (USask) Senate voted unanimously to transition the Division of Oncology to the Department of Oncology. This marks the final step in a long road and is a significant milestone for the College of Medicine. This decision reflects oncology's integral role within the institutions clinical and academic spheres.
Oncology is an active clinical and academic division with an existing complement of more than 80 faculty between Saskatoon and Regina. These members have made significant contributions to the academic mission of the college and university for over 40 years through participation at all levels of medical education, continuing medical education and research. Their dedication to teaching has been consistently recognized through various awards, both within the college and across campus.
The decision to grant department status to oncology elevates the program and reinforces the invaluable contributions of faculty members to education and research. Additionally, it underscores the college's commitment to fully engaging all its faculty members. It strengthens oncology's involvement in the leadership and governance structures of the College of Medicine. Furthermore, this move aligns USask with most Canadian medical schools, which already have stand-alone oncology departments. By offering a dedicated oncology department, USask and the SCA can better attract and retain talent, further advancing its mission in medical education, cancer research, and patient care.
Gyne Oncology Hosts Third Annual Precision Oncology Symposium
On Tuesday, March 5, 2024, Gynecologic Oncology hosted our third annual Precision Oncology Symposium. Led by Dr. Laura Hopkins, this meeting celebrated our prairie ovarian cancer research consortium, with scientists from Saskatchewan, Alberta and British Columbia joining our academic clinical team.
This year’s focus was on developing a unique and first-in-Canada program for ovarian cancer patients. This program will have its start as part of a research grant call, hosted by the Cancer Research Society. Our group received an invitation to submit a grant for $600,000 and we plan to enroll patients who are interested in a precision oncology approach to relapsed/progressive rare cancer sub-types. These cancers have been poorly studied and new information is badly needed.
This is unique because it will offer patients molecular sequencing and organoid development (an artificially grown mass of cells or tissue that resembles an organ) for functional drug repurposing screening. This will take the guess-work out of drug selection, providing clinicians with a list of ‘which drug is best’ (from our existing and approved drug options) as determined by testing the patient-derived organoid. Looking for drug targets in this ‘living tumour system’ has not been done anywhere in North America.
First Patient Receives CAR T Therapy in Saskatchewan
Saskatchewan’s CAR T team, comprised of dedicated health care providers at the SCA and SHA, was proud to deliver the revolutionary Chimeric Antigen Receptor T cell (CAR T) therapy to the very first patient in the province. We are thankful to now have this potentially life-saving treatment option available to eligible patients here in Saskatchewan.
Special thanks to the dedicated, hardworking and compassionate healthcare providers that make up the Stem Cell Transplant & Cellular Therapy team for everything you do to ensure our patients feel comfortable and supported throughout the transplant journey. The amazing work you do each and every day is saving lives and giving patients hope–patients like Cherylee Truitt, who was the first patient to receive CAR T treatment in the province. She is so appreciative and thankful for the support of her health care team. For more information on her journey so far, here is an excerpt from a recent SHA article:
Cherylee Truitt’s second birthday, as she calls it, has just passed, though she held off on the cake.
On May 17, she received a revolutionary therapy that is hoped to give her a second shot at life. Truitt has diffuse large B cell lymphoma, which made her a candidate for Chimeric Antigen Receptor T cell (CAR T) therapy, a treatment Saskatchewan began offering this spring. CAR T therapy uses a patient’s T cells which have essentially been supercharged so they can fight the patient’s cancer.
Until now, Saskatchewan patients referred for CAR T therapy travelled out of the province. Truitt is pleased the therapy is offered here, where her family, friends and her familiar care teams are within arm’s length.
“I’m never alone. They are just the best cheerleaders,” she said, noting her healthcare team members are just a call away anytime of the day or night. Truitt is grateful for the care she has received from so many people within and outside of the SHA and the SCA.
Read the full article.
Government Proclaims March as Multiple Myeloma Awareness Month
On March 13, 2024, the Government of Saskatchewan proclaimed March as Multiple Myeloma Awareness Month. Thanks to Trevor Ives, a multiple myeloma patient, and SCA Hematologist, Dr. Julie Stakiw for their dedication to raising awareness about this rare cancer.
Revolutionary CAR T Therapy Now Available in Saskatchewan
Saskatchewan patients with specific cancers can now receive an innovative type of immunotherapy closer to home. The Saskatchewan Cancer Agency (Cancer Agency), along with the Saskatchewan Health Authority (SHA), has launched the revolutionary Chimeric Antigen Receptor T-cell (CAR T) therapy to treat adult cancer patients with certain blood cancers and lymphomas in the province.
“We are pleased to now offer this revolutionary CAR T therapy in Saskatchewan, so that patients no longer need to travel out of province to take advantage of this potentially life-saving treatment,” Saskatchewan Cancer Agency President and CEO Deb Bulych said. “This exciting announcement would not be possible without the steadfast support from the Government of Saskatchewan, the Saskatchewan Health Authority and our health system partners.
The Government of Saskatchewan has provided initial funding of $2.128M to develop a commercial CAR T program and will provide an estimated $6.7M annually to operate the program and fund the cost of treatment for patients. The CAR T therapy program, available in Saskatoon, includes collecting a patient’s T-cells (a type of immune system cell) from their blood and then engineering them with genetic material to recognize and attack cancer cells. Those cells are multiplied and then infused back into the patient where they can get to work destroying the cancer cells in their body.
Establishing a CAR T therapy in Saskatchewan has involved the expertise and commitment of the Saskatchewan Stem Cell Transplant and Cellular Therapy Program (SCTCTP) team at the Cancer Agency and the SHA, as well as partners in neurology, ICU and others.
Saskatchewan Cancer Agency First in Canada to Use New Treatment for Brain Tumors
The Saskatchewan Cancer Agency (SCA) is implementing a new tool for treating metastatic brain cancer, marking an important milestone in cancer care. This month, the SCA treated the first patient in Canada using the HyperArc stereotactic radiosurgery system.
HyperArc is a state-of-the-art and highly efficient radiosurgery treatment planning and delivery system. The precision of the HyperArc system provides high-quality treatments with reduced side effects. It is the latest technology to be rolled out through the SCA’s stereotactic radiosurgery program expansion.
“The Saskatchewan Cancer Agency strives to provide care of the highest quality to each patient who walks through our doors. Introducing HyperArc to our radiotherapy treatment options means that patients can receive world-class treatment closer to home,” said Dr. Jon Tonita, President and CEO of the Saskatchewan Cancer Agency.
The move to HyperArc is the latest step in the journey to expand the stereotactic radiosurgery program. The SCA has been offering stereotactic radiosurgery since 2016. The Varian HyperArc system was installed at the Allan Blair Cancer Centre (ABCC) earlier this year, thanks to $3.5-million in funding from the Ministry of Health.
“Our government is committed to funding leading-edge technology to help improve health outcomes for patients being treated at the Saskatchewan Cancer Agency. The benefit to Saskatchewan residents is priceless. Congratulations to the employees at the Agency for their hard work in implementing this new lifesaving technology,” said Minister of Health Paul Merriman.
Stereotactic radiosurgery delivers precisely-targeted radiation in fewer high-dose treatments than traditional therapy, which can help preserve healthy brain tissue. “The field of radiosurgery is evolving rapidly, and I’m so proud of the SCA teams who worked over the past year to bring HyperArc to Saskatchewan. Providing patients with the most modern treatment available today is exciting and will lead to better outcomes and better quality of life for our patients with metastatic brain cancer,” said Dr. Gavin Cranmer-Sargison, Director of Medical Physics for the Saskatchewan Cancer Agency.
In 2020, the SCA treated 20 patients in Saskatoon using stereotactic radiosurgery. The recent program expansion at the ABCC in Regina will provide additional program capacity and treatment closer to home for many patients who live in southern Saskatchewan. In addition, the SCA will be rolling out HyperArc technology at the Saskatoon Cancer Centre later this year.
Awards
Dr. Kelsey Brose, Hematologist
Congratulations to Dr. Kelsey Brose, Hematologist and Assistant Professor, who recently received the University of Saskatchewan Provost’s College Award for Outstanding Teaching 2023!
“Give teaching a try. It comes in many forms and doesn’t have to be a lecture or presentation. It can be a conversation, a game, an interesting story, or whatever grabs the minds of your learners. Tailor it to the unique perspectives that you bring from your past experiences and see where it takes you.” – Dr. Kelsey Brose to the College of Medicine
This is great advice, Dr. Brose. Congratulations on this well-deserved award!
Dr. Vickie Martin, Gynecologic Oncologist
 |
Congratulations to Dr. Vickie Martin, Gynecologic Oncologist and USask Assistant Professor, Division of Oncology, for receiving the 2023 David Popkin Award for Excellence in Postgraduate Education.
Dr. Martin is recognized for her commitment to resident education and unwavering enthusiasm for the specialty. This is Dr. Martin's second major postgraduate medical education teaching award within the last two years. Congratulations, Dr. Martin!
|
Grants
SCA and Cancer Foundation of Saskatchewan Operating Grants Awarded
Congratulations to the following SCA researchers who were recently awarded SCA operating grants. The SCA and the Cancer Foundation of Saskatchewan provide funding for research initiatives through a yearly grant application process to help support bench research, clinical research including clinical trials, and epidemiology research.
Dr. Vijayananda Kundapur; Investigating minibeam radiation therapy for hepatocellular carcinoma
Liver cancer is a leading cause of cancer-related illness and death. Unfortunately, most patients with liver cancer are diagnosed with tumours too large to be treated with radiation therapy without a high risk of damaging their liver. Minibeam radiation therapy is a new approach to radiation delivery in which the radiation beam is divided into many narrow, parallel beams, or “minibeams”. This project will investigate the response of liver cancer and normal liver to minibeam radiation therapy, with the aim of translating the findings to human clinical trials, and ultimately to improve outcomes for liver cancer patients.
Dr. Julie Stakiw; Evaluating the epidemiology of smoldering multiple myeloma among Indigenous patients in Saskatchewan
Multiple myeloma (MM), although a rare disease, is the second most common hematologic malignancy. Smoldering multiple myeloma (SMM) is a type of myeloma that is not yet symptomatic. Diagnosing patients with this asymptomatic condition is clinically relevant because these patients can progress to multiple myeloma. Disparities in accessing standard of care treatment exist among socioeconomically marginalized patients with MM. Indigenous peoples are among the most marginalized patients within our health-care system. The goal of this study is to review Saskatchewan patients (those who self-identify as Indigenous versus non-Indigenous) with a history of smoldering myeloma and evaluate their disease characteristics and barriers to access to care.
Dr. Ibraheem Othman; Western Canadian Province Experience on Comparison of Second Autologous Stem Cell Transplant (ASCT) Versus Single ASCT for Patient With Multiple Myeloma (MM) : A Retrospective Population-Based Cohort Study
Autologous stem cell transplantation (ASCT) is the standard treatment of choice for eligible multiple myeloma (MM) patient. The role of second transplant in MM is debated. Tandem ASCT as an upfront treatment in cases with MM and its advantage over single ASCT are a matter of debate. On the other hand, many studies have investigated the efficacy of ASCT in the relapse MM. This study will evaluate the role of double ASCT in cases with MM using a retrospective chart review with data from the SCA. This includes demographic, transplant and post-transplant data from all patients diagnosed with MM who underwent autologous stem cell transplantation between the years 2010-2020.
Dr. Franco Vizeacoumar; Validating synthetic lethal interactions within the DNA damage and response pathways
Cancer cells contain damaged DNA and this makes them more sensitive to changes in genes that control the DNA damage repair pathways and other genes that depend on these functions for the cancer cells to survive. Dr. Vizeacoumar’s lab used a bioinformatic (i.e. computational) approach to identify genetic relationships between genes involved in DNA damage and repair. In this grant, they will test these predictions experimentally to validate their requirement in triple-negative breast cancer models.
Dr. Deborah Anderson; New drugs for metastatic luminal A breast cancer
About 73% of all breast cancers are of the luminal A subtype that express the estrogen receptor and are treated with anti-estrogens. Some of these cancers do not respond, or over time develop resistance to these treatments and become metastatic. Our laboratory has been studying a metastasis suppressor called CREB3L1 whose expression is lost in ~30% of breast cancers and is associated with more advanced metastatic disease and a poor prognosis in luminal A breast cancers. In this project, we will identify new drugs that are effective against the most metastatic luminal A breast cancers as new treatments for metastatic disease.
CIHR Operating Grants Awarded to SCA Researchers
Congratulations to Dr. Deborah Anderson, SCA’s Director of Research, and Dr. Franco Vizeacoumar, Senior Scientist, on securing operating grants from the Canadian Institutes of Health Research (CIHR).
Dr. Anderson’s grant ranked first in the Cancer Progression and Therapeutics panel and was awarded $504,900 over two years for her project titled Targeting Metastatic Breast Cancer.
Dr. Anderson and her team are developing new drugs for a novel cancer target called CLIC3. In laboratory studies, blocking CLIC3 function slows tumour growth and, importantly, prevents spread to other parts of the body. The team is hopeful that we can make novel drugs to block metastasis in patients with a particularly aggressive subtype of breast cancer called triple negative breast cancer. You can learn more about Dr. Anderson’s project in the news release issued by the University of Saskatchewan.
Dr. Vizeacoumar and his team of esteemed researchers from the U of S and McGill have been awarded $100,000 in bridge funding under the Breast Cancer Research Priority Announcement for their project, titled Targeting the EGFR/EphA2 Crosstalk in Triple Negative Breast Cancer (TNBC).
TNBC is the most aggressive form of breast cancer and this team will develop novel combination therapy for its treatment.
New Grant Funding for SCA Researchers
Congratulations to the SCA Research department for securing two new operating grants from the Canadian Institutes of Health Research (CIHR). These grants are very challenging to obtain, with success rates of around 15% nationally.
Director of Research Dr. Deborah Anderson’s grant ranked first in the Cancer Progression and Therapeutics panel and was awarded $504,900 over two years for her project titled Targeting Metastatic Breast Cancer. Dr. Anderson and her team are developing new drugs for a novel cancer target called CLIC3. In laboratory studies, blocking CLIC3 function slows tumour growth and, importantly, prevents spread to other parts of the body. The team is hopeful that we can make novel drugs to block metastasis in patients with a particularly aggressive subtype of breast cancer called triple negative breast cancer.
Dr. Franco Vizeacoumar, Senior Scientist, collaborates with a team of esteemed researchers from the University of Saskatchewan, including Drs. Freywald and Dadachova, as well as McGill researcher Dr. Bisson. Together, they have been awarded $100,000 in bridge funding under the Breast Cancer Research Priority Announcement. The financial support for their project, titled Targeting the EGFR/EphA2 Crosstalk in Triple Negative Breast Cancer (TNBC), is generously provided by the CIHR Institute of Cancer Research (ICR).
TNBC is the most aggressive form of breast cancer and the work of Drs. Vizeacoumar and Freywald along with their team will develop novel combination therapy for its treatment. Notably, this marks Dr. Vizeacoumar's sixth successful grant supported by CIHR, comprising four full grants (totaling $2,708,103) apart from two bridge grants (amounting to $200,000) over the past decade.
Kudos to the SCA Research team on their achievements and these groundbreaking projects!
New Ovarian Cancer Patient Decision Aid Developed
Congratulations to Dr. Laura Hopkins, Gynecological Oncology Provincial Lead, who was awarded a grant in the amount of $20,000 from the Saskatchewan Health Research Foundation in August 2022. Dr. Hopkins and her team of patient partners and content experts developed the first ovarian cancer decision aid for the setting of PARPi maintenance therapy—a new class of cancer drug.
Patient decision aids are tools to help people make informed choices about their health care that take into account their personal values and preferences. Decision aids provide information about options and outcomes, and are especially useful in circumstances where the best treatment option is not clear and/or when a patient’s personal priorities and feelings can be expected to impact the decision for or against a treatment or a test.
Kudos to Dr. Hopkins and her team on this achievement!
SCA Genetic Testing Pilot Program Wins Grant
Congratulations to SCA’s Dr. Mita Manna, Medical Oncologist, who was awarded a $100,000 grant from the Royal University Hospital Foundation’s Women Leading Philanthropy. The grant will fund her pilot project: Mainstream Genetic Testing: A Pilot Program in Saskatchewan, which aims to transform health care for breast and ovarian cancer patients and, ultimately, save lives.
Breast cancer is the most common type of cancer for women in North America and ovarian cancer is the most terminal gynecological cancer. Ten to 15 per cent of breast and ovarian cancers are due to genetic changes, which are also known as “mutations.” These mutations in BReast CAncer (BRCA) genes are inherited and can substantially increase an individual’s risk of developing breast and ovarian cancer.
Currently, in Saskatchewan, women with breast cancer can wait up to four to five years to undergo genetic testing for mutations in the BRCA genes. A delay in identifying these mutations can have serious consequences for women and their families, including lower life expectancy and a higher cancer risk for their relatives.
Dr. Manna’s pilot project proposes the use of “mainstreaming” to improve access to timely genetic testing. This new process would allow cancer clinicians, such as surgeons or oncologists, to easily order these tests for their patients without a prior consultation with genetic counsellors. When mutations are identified, those patients will be quickly referred to medical genetics at the Royal University Hospital for follow-up services.
Results of this promising study will be shared with health care professionals and advocacy groups to promote best practices and further research. We look forward to hearing more on this potentially life-saving project.
Researchers Awarded SCA Operating Grants
Congratulations to the following SCA researchers who were recently awarded SCA operating grants. The SCA provides funding for research initiatives through a yearly grant application process to help support bench research, clinical research including clinical trials, and epidemiology research.
Dr. Dean Chamberlain; Breast Cancer Tumouroids to study the role of Hypoxia and Cancer Stem Cells in Drug Resistance
The Chamberlain research group is focused on building the new generation of tools required to better understand tumour biology and invent cutting edge therapies. This SCA grant will develop a 3D artificial tumour model of breast cancer. This 3D tumour model will then be used to study the interactions within the tumour that regulate the development of cancer stem cells.
Dr. Shruthi Kodad; Enhancing the Quality of CLL patient Care Using Optical Genomic Mapping and Minimal Residual Disease Monitoring
Optical genomic mapping (OGM) is a high-resolution mapping technique, while minimal residual disease (MRD) monitoring is used to see if the cancer treatment is working and to predict disease relapse. This research will use both of these tools with patients who have chronic lymphocytic leukemia (CLL) to look for genetic abnormalities, which can guide further treatment plans and aid in future studies.
Congratulatory Notes
Under Construction
Clinical Trials & Research
Under Construction
Publications & Presentations
CME
Saskatchewan Cancer Education Program - Online Oncology Modules for Family Physicians and Nurse Practitioners
The SCA’s cancer care specialists have collaborated with Continuing Medical Education (CME) at USask's College of Medicine on an accredited Saskatchewan Cancer Education program to facilitate cancer education and care of patients with cancer in the community.
The 11 online modules (listed below) are available on CME's website for primary care physicians and nurse practitioners who are involved in the care of patients with cancer. This collaborative work is an important step to promote oncology education in the community and improve care for Saskatchewan patients.
The modules cover a vast range of areas in cancer care including early diagnosis and screening, treatment, management of side effects of novel cancer therapy and survivorship care, and involve key disciplines such as medical oncology, malignant hematology, radiation oncology and gynecological oncology.
The modules include:
- Immunotherapy Toxicity Management - Presented by Dr. Osama Souied
- Oncologic Emergencies - Presented by Dr. Kimberly Hagel
- Survivorship Care for Lung Cancer Patients - Presented by Dr. Ayesha Bashir
- Colon Cancer Follow-up - Presented by Dr. Adnan Zaidi
- Screening for Prostate Cancer - Presented by Dr. Nelson Leong
- Active Surveillance for the Family Physician - Presented by Dr. Nelson Leong
- Androgen Deprivation Therapy - Presented by Dr. Nelson Leong
- HPV and Cervical Dysplasia - Presented by Dr. Shaina Lee
- Ovarian cancer and opportunistic salpingectomy as a tool for preventing ovarian cancer - Presented by Dr. Shaina Lee
- 10. Multiple Myeloma - Presented by Dr. Ibraheem Othman
- 11. Endometrial Cancer Management from Diagnosis to Follow-up - Dr. Shaina Lee
This work was made possible with the support of Dr. Osama Souied (Project Lead), Dr. Kimberly Hagel, Dr. Ayesha Bashir, Dr. Adnan Zaidi, Dr. Nelson Leong, Dr. Shaina Lee, Dr. Ibraheem Othman, Dr. Shahid Ahmed (SCA Academic Director),
Dr. Jim Barton (Associate Dean CME), Carolyn Hoessler, Emily Parker and many others.
Events
Loading...
Contact
Interim Department Head
Dr. Shahid Ahmed, MD, PhD, FACP, FRCPC
Professor
20 Campus Drive
Saskatoon Cancer Centre
University of Saskatchewan
Saskatoon, SK S7N 4H4
Phone: 306-655-2710
Fax: 306-655-0633
Administrative Contact
Karly Struck
Phone: 306-655-2744
Fax: 306-655-0633